Oncology

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in multiple myeloma patients.

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

Although highly efficacious, patient selection and adverse event management are crucial.

Discover how the combination of palbociclib, trastuzumab, and endocrine therapy enhances survival in HER2-positive advanced breast cancer patients.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

Pirtobrutinib’s indication was expanded for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, allowing for treatment in earlier lines of therapy.

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

A cohort study of over 6 million US veterans revealed a 76% increased risk of pancreatic cancer following chronic hepatitis C infection.

The blood test helps patients avoid unnecessary and invasive biopsies.

Sam Klempner, MD, discusses early findings for the bispecific T-cell engager ASP2138, including monotherapy response, combination activity, and safety enhancements through subcutaneous dosing.

Long-term follow-up data showed that about 50% of patients achieved the trial's primary end point.

New research uncovers diverse tumor subgroups in triple-negative breast cancer, paving the way for personalized treatment strategies and improved patient outcomes.

Expanding lung cancer screening to an age-based model significantly enhances early detection, potentially saving over 26,000 lives annually in the US.

Research funding disruptions at the National Institutes of Health (NIH) impact clinical trials, threatening treatment options for patients and highlighting the critical role of pharmacists in care continuity.

High-dose busulfan-melphalan enhances VRd therapy, improving progression-free survival in high-risk multiple myeloma patients undergoing ASCT.

CAR T-cell therapy shows promise for treating HER2-positive breast cancer with CNS metastases, offering a novel approach to improve patient outcomes.

The FDA approved durvalumab with FLOT chemotherapy, revolutionizing treatment for early gastric and gastroesophageal junction cancers, enhancing survival rates.

The combination has the potential to redefine the standard of care for a population that previously had limited therapeutic avenues.

New studies reveal a modest, temporary increase in breast cancer risk linked to hormonal contraceptives, emphasizing the need for informed patient counseling.

Advanced IHC assays enhance HER2-low breast cancer detection, improving treatment eligibility for trastuzumab deruxtecan.

The biosimilars can be used to treat osteoporosis and cancer-related bone loss in certain populations.